Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients

The aim of this study was to compare the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptor blocker on aortic systolic blood pressure (BP) and brachial ambulatory systolic BP. We conducted a prospective, randomized, open-label, blinded end point study in 207 hypertensive patients (mean age: 68.4 years). Patients received olmesartan monotherapy for 12 weeks, followed by additional use of azelnidipine (n=103) or hydrochlorothiazide (n=104) for 24 weeks after randomization. The central BP by radial artery tonometry, aortic pulse wave velocity, and ambulatory BP were assessed at baseline and 24 weeks later. After adjustment for baseline covariates, the extent of the reduction in central systolic BP in the olmesartan/azelnidipine group was significantly greater than that in the olmesartan/hydrochlorothiazide group (the between-group difference was 5.2 mm Hg; 95% CI: 0.3 to 10.2 mm Hg; P=0.039), whereas the difference in the reduction in brachial systolic BP between the groups was not significant (2.6 mm Hg; 95% CI: −2.2 to 7.5 mm Hg; P=0.29). The aortic pulse wave velocity showed a significantly greater reduction for the olmesartan/azelnidipine combination than for the olmesartan/hydrochlorothiazide combination (0.8 m/s; 95% CI: 0.5 to 1.1 m/s; P<0.001) after adjustment for covariates. The extent of the reduction in brachial ambulatory systolic BP was similar between the groups. These data showed that the combination of olmesartan (20.0 mg) and azelnidipine (16.0 mg) had a more beneficial effect on central systolic BP and arterial stiffness than the combination of olmesartan (20.0 mg) and hydrochlorothiazide (12.5 mg), despite the lack of a significant difference in brachial systolic BP reduction between the 2 treatments.

[1]  P. Challande,et al.  Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. , 2009, American journal of hypertension.

[2]  D. Rizzoni,et al.  Effects of antihypertensive treatment on small artery remodelling , 2009, Journal of hypertension.

[3]  H. Koike,et al.  Chronotropic Effects of Azelnidipine, a Slow- and Long-acting Dihydropyridine-type Calcium Channel Blocker, in Anesthetized Dogs: A Comparison With Amlodipine , 2009, Journal of cardiovascular pharmacology.

[4]  T. Kohro,et al.  Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design , 2009, Hypertension Research.

[5]  B. Dahlöf.  Management of cardiovascular risk with RAS inhibitor/CCB combination therapy , 2009, Journal of Human Hypertension.

[6]  J. Lekakis,et al.  The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part I: (Patho)-physiology, rationale and perspective on pulse pressure amplification. , 2009, Current pharmaceutical design.

[7]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[8]  Riccardo Pini,et al.  Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. , 2008, Journal of the American College of Cardiology.

[9]  Yasmin,et al.  A comparison of atenolol and nebivolol in isolated systolic hypertension , 2008, Journal of hypertension.

[10]  S. Ito,et al.  Clinical Study with Azelnidipine in Patients with Essential Hypertension , 2007, Arzneimittelforschung.

[11]  Y. Imai,et al.  Monitoring of antihypertensive therapy for reduction in left ventricular mass. , 2007, American journal of hypertension.

[12]  G. Mancia,et al.  Central blood pressure measurements and antihypertensive therapy: a consensus document. , 2007, Hypertension.

[13]  K. Node,et al.  Azelnidipine Reduces Urinary Protein Excretion and Urinary Liver-Type Fatty Acid Binding Protein in Patients with Hypertensive Chronic Kidney Disease , 2007, The American journal of the medical sciences.

[14]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[15]  M. O'Rourke,et al.  Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure , 2007, Journal of hypertension.

[16]  K. Asayama,et al.  Current Usage of Diuretics among Hypertensive Patients in Japan: The Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study , 2006, Hypertension Research.

[17]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[18]  Yasmin,et al.  Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. , 2006, American journal of hypertension.

[19]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[20]  M. Safar,et al.  Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. , 2004, Journal of the American College of Cardiology.

[21]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[22]  M. Safar,et al.  Clinical Utility of Aortic Pulses and Pressures Calculated From Applanated Radial-Artery Pulses , 2003, Hypertension.

[23]  T. Ogihara,et al.  Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[24]  Morris J. Brown,et al.  Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. , 2002, Clinical science.

[25]  P. Lantelme,et al.  Heart Rate: An Important Confounder of Pulse Wave Velocity Assessment , 2002, Hypertension.

[26]  R. Asmar,et al.  Validation of the Omron HEM-907 device for blood pressure measurement , 2002, Blood pressure monitoring.

[27]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[28]  G. London,et al.  Different Aortic Reflection Wave Responses Following Long‐Term Angiotensin‐Converting Enzyme Inhibition And Beta‐Blocker In Essential Hypertension , 2001, Clinical and experimental pharmacology & physiology.

[29]  M. O'Rourke,et al.  Prospective Evaluation of a Method for Estimating Ascending Aortic Pressure From the Radial Artery Pressure Waveform , 2001, Hypertension.

[30]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[31]  P. Ducimetiere,et al.  Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients , 2001, Hypertension.

[32]  D. Webb,et al.  The influence of heart rate on augmentation index and central arterial pressure in humans , 2000, The Journal of physiology.

[33]  P. Palatini,et al.  Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects' characteristics. , 1998, Blood pressure monitoring.

[34]  M. Safar,et al.  Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. , 1993, The American journal of cardiology.